---
document_datetime: 2025-07-14 11:06:18
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/evrysdi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: evrysdi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.2789005
conversion_datetime: 2025-12-29 23:10:38.359082
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Evrysdi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| X/0024/G             | This was an application for a group of variations. Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 27/03/2025                          | 02/06/2025                                  | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | data Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |      |                                                                                                                                                                                                               |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10925 /202408 | Periodic Safety Update EU Single assessment - risdiplam                                                                                                                                                                                                                                                                                                                                                                                                               | 13/03/2025 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                             |
| IA/0028             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                          | 14/10/2024 | n/a        |      |                                                                                                                                                                                                               |
| II/0027             | Submission of the final report from study BP39056 (FIREFISH) listed as a category 3 study in the RMP; this is a two-part seamless, open-label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of risdiplam in infants with type 1 spinal muscular atrophy. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 05/09/2024 | n/a        |      | Submission of the final report from study BP39056.                                                                                                                                                            |
| PSUSA/10925 /202402 | Periodic Safety Update EU Single assessment - risdiplam                                                                                                                                                                                                                                                                                                                                                                                                               | 05/09/2024 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                             |
| II/0022             | Submission of the final report from study 'BP39055 (SUNFISH)' listed as a category 3 study in the RMP. Study BP39055 is a Two-Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of                                                                                                                                                              | 25/07/2024 | 21/10/2024 | SmPC | Update of the SmPC section 5.2 with results from SUNFISH study, with the mean exposure and Cmax following 5 years of treatment. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                                      |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0025             | Update of sections 4.4, 4.5 and 5.3 of the SmPC in order to remove the warning on retinal toxicity, based on thorough ophthalmological monitoring in clinical studies to date. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                       | 11/07/2024 | 21/10/2024 | SmPC        | Update of the SmPC in order to remove the warning on retinal toxicity. For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10925 /202308 | Periodic Safety Update EU Single assessment - risdiplam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 07/03/2024 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                    |
| II/0021             | Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information based on primary analysis results from study BN40703 (RAINBOWFISH); this is an open-label, single-arm, multicenter clinical study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of risdiplam in patients aged from birth to 6 weeks (at first dose) who are genetically diagnosed with SMA (SMN1 deletion and any SMN2 copies) but not yet presenting with symptoms. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the Instructions for Use. | 01/02/2024 | 21/10/2024 | SmPC and PL | For more information, please refer to the Summary of Product Characteristics.                                                                        |

<div style=\"page-break-after: always\"></div>

|         | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020 | Submission of an updated RMP version 2.0 in order to remove the important potential risk of retinal toxicity with risdiplam due to the absence of evidence of retinal toxicity based on thorough ophthalmological monitoring in clinical studies to date. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH | 11/01/2024 | n/a        |             | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0018 | Update of section 5.3 of the SmPC in order to update carcinogenicity information based on final results from study 8447237. This is a 104 Week Oral (Gavage) Administration Carcinogenicity Study in the Wistar Rat to investigate the tumorigenic potential of Evrysdi. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data        | 07/12/2023 | 21/10/2024 | SmPC and PL | Section 5.3 of the SmPC has been updated in order to add carcinogenicity information based on final results from study 8447237. This is a 104 Week Oral (Gavage) Administration Carcinogenicity Study in the Wistar Rat to investigate the tumorigenic potential of Evrysdi. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| II/0017             | Update of section 5.1 of the SmPC in order to add information on cardiac electrophysiology based on final results from study BP42817 (QTc Study), listed as a category 3 PASS in the RMP. This is a Phase 1, double-blind, placebo and positive controlled crossover study to investigate the effects of risdiplam on QTc interval in healthy subjects. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                         | 30/11/2023   | 21/10/2024   | SmPC                   | Section 5.1 of the SmPC has been updated in order to add information on cardiac electrophysiology based on final results from study BP42817 (QTc Study), listed as a category 3 PASS in the RMP. This is a Phase 1, double- blind, placebo and positive controlled crossover study to investigate the effects of risdiplam on QTc interval in healthy subjects. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10925 /202302 | Periodic Safety Update EU Single assessment - risdiplam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31/08/2023   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0005/G           | This was an application for a group of variations. Extension of indication to include treatment of patients below 2 months of age based on interim results from study BN40703 (RAINBOWFISH). The pivotal study RAINBOWFISH is an ongoing phase II multicentre, open-label, and single-arm study designed to evaluate the efficacy, safety, tolerability, and PK/PD of risdiplam in pre-symptomatic infants below 2 months of age who were genetically diagnosed with SMA. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to make some editorial improvements in the product information. A revised RMP version 1.1 was also submitted as part of the application. | 20/07/2023   | 16/08/2023   | SmPC, Labelling and PL | Please refer to Scientific Discussion 'EMEA/H/C/001899/II/0005/G                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                     | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one B.IV.1.b - Change of a measuring or administration device - Deletion of a device B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                     |            |            |      |                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0011             | Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to delete an existing warning on 'Use with SMA gene therapy' and to update the safety profile and efficacy data in patients previously treated with other SMA-modifying therapies based on the 24- month primary analysis data from study BP39054 (JEWELFISH); this is a multicenter, open-label study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of risdiplam in adult and paediatric patients with SMA. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 20/04/2023 | 16/08/2023 | SmPC | Section 4.4 has been updated to delete an existing warning on 'Use with SMA gene therapy'. Sections 4.8 and 5.1 have been updated to add information on the safety and efficacy profiles in patients previously treated with other SMA-modifying therapies based on JEWELFISH study. Section 5.2 has been updated with PK data from the same study. |
| PSUSA/10925 /202208 | Periodic Safety Update EU Single assessment - risdiplam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/03/2023 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IB/0014/G   | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging   | 22/02/2023   | n/a        |    | site      |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-----------|
|             | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                | 03/02/2023   | n/a        |    | IB/0015/G |
| N/0012      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                           | 01/02/2023   | 16/08/2023 | PL |           |
| IA/0013     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                               | 20/12/2022   | n/a        |    |           |
| IAIN/0009/G | This was an application for a group of variations. B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging -                                                                                                                                                                            | 13/10/2022   | n/a        |    |           |

<div style=\"page-break-after: always\"></div>

|                     | Device with CE marking B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                |            |            |             |                                                                                                                                                                                                                                              |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10925 /202202 | Periodic Safety Update EU Single assessment - risdiplam                                                                                                                                                                                                                                                                                                                                                          | 01/09/2022 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                            |
| IB/0006             | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                         | 17/06/2022 | 21/09/2022 | SmPC and PL |                                                                                                                                                                                                                                              |
| IA/0007             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                       | 28/03/2022 | n/a        |             |                                                                                                                                                                                                                                              |
| PSUSA/10925 /202108 | Periodic Safety Update EU Single assessment - risdiplam                                                                                                                                                                                                                                                                                                                                                          | 10/03/2022 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                            |
| II/0003             | Update of section 4.8 of the SmPC to add undesirable effects based on post-marketing experience. The Package Leaflet (PL) is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the contact details of local representatives in the PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 18/11/2021 | 21/09/2022 | SmPC and PL | Section 4.8 of the SmPC has been updated to include Cutaneous Vasculitis as an undesirable effect with frequency not known based on post-marketing experience. For more information, please refer to the Summary of Product Characteristics. |
| II/0002             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                                     | 28/10/2021 | 21/09/2022 | SmPC and PL |                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | data                                                                                           |            |     |
|---------|------------------------------------------------------------------------------------------------|------------|-----|
| IB/0001 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 26/05/2021 | n/a |